The Sonic Hedgehog (SHH) signaling pathway is indispensable for development, and functions to activate a transcriptional program modulated by the GLI transcription factors. Here, we report that loss of a regulator of the SHH pathway, Suppressor of Fused (Sufu), resulted in early embryonic lethality in the mouse similar to inactivation of another SHH regulator, Patched1 (Ptch1). In contrast to Ptch1 þ /À mice, Sufu þ /À mice were not tumor prone. However, in conjunction with p53 loss, Sufu þ /À animals developed tumors including medulloblastoma and rhabdomyosarcoma. Tumors present in Sufu
À/À animals resulted from Sufu loss of heterozygosity. Sufu
À/À medulloblastomas also expressed a signature gene expression profile typical of aberrant SHH signaling, including upregulation of N-myc, Sfrp1, Ptch2 and cyclin D1. Finally, the Smoothened inhibitor, hedgehog antagonist, did not block growth of tumors arising from Sufu inactivation. These data demonstrate that Sufu is essential for development and functions as a tumor suppressor.
Oncogene ( Keywords: suppressor of fused; sufu; patched1; medulloblastoma; hedgehog; HhAntag Aberrant regulation of growth signaling during development can result in tumor formation. A well-studied example of this is disruption of the Sonic Hedgehog (SHH) pathway. SHH is a secreted glycoprotein that is important for the differentiation, patterning and polarity of various tissues (Lum and Beachy, 2004; Hooper and Scott, 2005; Dellovade et al., 2006) . The interaction of SHH with its transmembrane receptor, Patched1 (PTCH1) relieves repression of Smoothened (SMO), allowing SMO to activate SHH signaling which ultimately leads to transcriptional activity of the GLI transcription factors. Germline mutation of PTCH1 can lead to medulloblastoma and basal cell carcinoma (Lum and Beachy, 2004; Hooper and Scott, 2005; Marino, 2005; Dellovade et al., 2006) .
As the signaling cascade controlled by SHH involves gene expression changes effected by the GLI transcription factors, fine-control of these factors is centrally important during development. The molecular mechanism for regulation of GLI function is not completely understood, but involves the serine/threonine kinase fused (Fu), suppressor of fused (Sufu) and the kinesin-like protein costal2 (Cos2) (Lum and Beachy, 2004; Hooper and Scott, 2005; Svard et al., 2006) . In Drosophila, these components form a complex with Smo and Ci (GLI) by a scaffolding function of Cos2, when SHH is not present. Binding of SHH to Ptch1 results in Ci release from the complex thereby abrogating repression of Ci. In contrast to Drosophila, neither Cos2 orthologs nor Fu were required for proper SHH signaling in mammals (Chen et al., 2005; Varjosalo et al., 2006) , whereas Sufu was found to be a critical component of the SHH pathway in higher organisms (Cooper et al., 2005; Svard et al., 2006; Varjosalo et al., 2006) . Finally, like Ptch1, a subset of medulloblastoma patients carried germline and somatic SUFU mutations implicating SUFU as a tumor suppressor (Taylor et al., 2002) .
To further delineate the role of Sufu during development and in the prevention of tumorigenesis, we generated mice carrying a Sufu mutation obtained via a gene-trap approach. Interbreeding Sufu þ /À mice did not yield any live Sufu À/À animals. We also failed to obtain live homozygous embryos after embryonic day 10 (E10.5) and subsequently determined that Sufu À/À embryos died in utero around E10 due to defects in neural tube closure and heart abnormalities, similar to those found in Ptch1 À/À embryos (data not shown). The early embryonic lethality of our Sufu À/À animals was consistent with two other independent lines of Sufu knockout animals recently reported in which mice lacked exon 1 or exon 7 (Oliver et al., 2005; Svard et al., 2006) . In contrast, our Sufu mutant lacks the last exon and part of 3 0 UTR, involving a region critical for Gli binding (Dunaeva et al., 2003) . Therefore, these three different targeting strategies all lead to a similar if not identical phenotype. Although loss of Sufu was not compatible with viability, Sufu heterozygous animals were indistinguishable from their wild-type littermates and were not prone to tumorigenesis during their normal life span. This contrasts the situation for Ptch1 þ /À mice where medulloblastoma and rhabdomyosarcoma are frequently observed (Goodrich et al., 1997) .
We therefore determined the effect of additional genetic alterations for tumorigenesis in Sufu þ /À by introducing p53 mutation. Although a p53 null background did not affect the embryonic lethality of Sufu À/À embryos, it dramatically influenced tumorigenesis in Sufu þ /À animals in similar manner to Ptch1 þ /À animals (Wetmore et al., 2001) , with the occurrence of medulloblastoma and rhabdomyosarcoma (Figure 1a) . Consistent with medulloblastoma formation, the distribution of Sufu expression in the postnatal day 7 (P7) developing brain using Lac Z staining from the b-geo gene-trap in the Sufu gene, showed strong staining in the external granule layer (EGL) of the cerebellum, suggesting Sufu functions during cerebellar development (Figure 1b) . Histopathological examination revealed that medulloblastomas from the Sufu
mice expressed markers typical of these tumors including synaptophysin, b-tubulin III (Tuj1) and glial fibrillary acidic protein (GFAP), and showed increased apoptosis ( Figure 1c ). The median survival period of Sufu
À/À animals (4 months) was longer than that of Ptch1
À/À animals (2 months), indicating Ptch1 mutations are more potent than Sufu mutations in reducing tumor latency. These animals also developed rhabdomyosarcoma (average onset 5 months) and lymphoma/thymoma ( Figure 1a ). Although formation of medulloblastoma and rhabdomyosarcoma resulted from the Sufu mutation, lymphoma in these animals was likely due to p53 deficiency (Jacks et al., 1994) . We did not observe medulloblastoma or rhabdomyosarcoma in p53
Human medulloblastomas with SUFU mutations show loss of heterozygosity (LOH) of the wild-type allele (Taylor et al., 2002) . To determine if tumors in Sufu
À/À arise by inactivation of the remaining Sufu allele, we examined Sufu status in the tumors at the mRNA and genomic level. To measure the expression level of Sufu, we designed two primer/probe sets for real-time polymerase chain reaction (PCR). One primer set (Sufu-a) detects expression of both the wild-type and the mutant allele, whereas the other set (Sufu-b) recognizes a region missing from the mutant allele and so only detects Sufu mRNA from the wild-type allele ( Figure 2a ). The expression level of Sufu measured by
Kaplan-Meier survival analysis (Po0.05, Logrank test) together with tumor incidence for each genotype. Sufu-deficient mice were generated by blastocyst injection of a targeted ES cell line was obtained from BayGenomics (http://baygenomics.ucsf.edu; clone#XB699) in which the last exon and 3 0 UTR of the Sufu gene were interrupted by a b-Geo cassette resulting from a gene trap insertion strategy. This mutation resulted in nucleotides 1482-1639 missing in Sufu mRNA (Genbank; NM_015752), leading to a truncated protein in which the GLI-interacting region is missing (Dunaeva et al., 2003) . All animals were maintained on a mixed genetic background (129Ola Â C57BL/6). 
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either primer/probe set was higher in the developing cerebellum than in the adult cerebellum in all genotypes tested due to high expression of Sufu in the EGL (Figure 2a , and see Figures 1b and 3a) . Analysis of
medulloblastoma using the Sufu-a primer/probe set showed a comparable level of Sufu to controls, whereas no Sufu was detectable using the Sufub probe set indicating that in these medulloblastomas þ /À p53 À/À medulloblastoma. Sufu expression was measured using two different primer/probe sets that distinguish mRNA from the mutant allele (Sufu-a, present in WT and mutants; left panel) and the WT allele (Sufu-b, present in WT only; right panel). Total RNA samples were extracted from snap frozen tumor samples and control tissues using Trizol (Invitrogen, Carlsbad, CA, USA). Real-time PCR methods were as detailed before (Lee et al., 2003 Figure 2 ). For arrayCGH analysis, genomic DNA from medulloblastoma (six Sufu þ /À p53 À/À and four Ptch1 þ /À p53 À/À ) was isolated using DNeasy Tissue Kit (Qiagen, Valencia, CA, USA). The murine BAC arrays composed of 6500 RPCI-23 and RPCI-24 clones were obtained from Roswell Park Cancer Institute (RPCI). The reference samples (WT male or female genomic DNA) were labeled with indocarbocyanine (Cy3), whereas the tumor genomic DNA samples were labeled with indodicarbocyanine (Cy5). After hybridization and washing, fluorescence intensity was detected using ScanArray5000 (Packard Instruments, Meriden, CT, USA) and Genepix 4000B (Axon Instruments, Union City, CA, USA) scanners. (c) Representative Spectral Karyotyping (SKY) of chromosome 19 of Sufu þ /À p53 À/À and Ptch1 þ /À medulloblastoma. SKY images show the spectral color image on the left and the pseudocolored chromosome on the right. Medulloblastoma primary tumors (two Sufu þ /À p53 À/À and three Ptch1 þ /À ) were collected 4 h after colcemid (Sigma) treatment, and were subject to SKY analysis according to the SkyPaint hybridization and detection protocol (Applied Spectral Imaging, Austin, TX, USA) using a commercially prepared SKY probe. MB: medulloblastoma. 
p53
À/À medulloblastoma suggests persistent SHH signaling, Gli expression was not upregulated in Sufu mutant medulloblastoma like in Ptch1 þ /À medulloblastoma. In cell culture experiments, knock-down of Sufu leads to aberrant activation of the SHH pathway and substantial induction of Gli1 transcriptional activity in a similar pattern to a loss of Ptch1 (Varjosalo et al., 2006) . On the contrary, our data show that this is not the case in Sufu þ /À p53 À/À medulloblastoma and might therefore reflect anomalous expression patterns that can occur in vitro compared to tumors (Sasai et al., 2006) . However, while we cannot completely rule out the possibility that a truncated Sufu protein may be partially functional, our Sufu À/À phenotype argues for a similar SHH signaling defect to that present in Ptch1 À/À embryos. It is also possible that the activity of Gli proteins does not fully mirror the level of mRNA of the Gli genes, although Gli1 may not be absolutely essential for medulloblastoma formation in all settings (Weiner et al., 2002; Kimura et al., 2005) . Given that Sufu can modulate Gli1 expression by repression of transcription via the SAP18-mSin3 histone deacetylase complex (Cheng and Bishop, 2002; PacesFessy et al., 2004) , then low Gli1 levels may not accurately reflect the effects of Sufu loss on Gli activity. Additional negative regulator(s) might also exist and act downstream of Ptch1 in parallel to Sufu (Lawinger et al., 2000; Ferretti et al., 2005) .
To further determine how Sufu þ /À p53 À/À medulloblastoma relates to altered SHH signaling we used the Hedgehog (Hh) antagonist (HhAntag). This Hh medulloblastoma. (a) Hierarchical cluster analysis of a selective group of genes differentially expressed in the medulloblastomas (MB) using Affymetrix MOE430A and B, and analysed using GeneSpring (v7.0, Agilent Technologies, Santa Clara, CA, USA) as described previously (Lee et al., 2003) . Tumor samples were compared to either WT-or p53-deficient cerebellum at P5 or 3 months (adult) of age. The first column shows the address on the gene chips and the second column shows the GenBank accession number of the genes. Asterisks indicate multiple hits of the same gene. High (red) to low (blue) expression changes ranging from 0 to 2.5 of normalized values. A total of 154 genes (60 genes upregulated and 94 genes downregulated) were differentially expressed in the tumors (see Supplementary Figure 1 antagonist can eliminate medulloblastoma arising in Ptch1 þ /À animals by suppression of the SHH pathway via Smo inhibition (Romer et al., 2004 ). Therefore, we tested whether HhAntag is effective toward Sufu mutant medulloblastoma, as Sufu regulates SHH signaling at the level of the Gli transcription (Lum and Beachy, 2004) . Sufu
À/À medulloblastoma samples were obtained from either primary tumors (cases III and IV) or allografts passaged in NOD/SCID mice (cases I and II), and were grown in nude mice (Figure 4a) . In all cases, tumors were Sufu À/À as determined by PCR and cytogenetic analyses (data not shown). Separate groups of Sufu
À/À medulloblastoma allografts as a positive control, were treated twice a day for 4 days with the HhAntag or vehicle. In three of four cases, HhAntagtreated Sufu
À/À medulloblastoma allografts maintained steady growth, suggesting that the drug was not effective toward Sufu þ /À tumors. In contrast, Ptch1 mutant medulloblastoma allografts treated in parallel and used as a positive control were responsive to HhAntag (Figure 4a ). Additionally, real-time PCR analysis of drug-treated allografts showed that HhAntag failed to affect medulloblastoma signature gene expression (Figure 4b ). This non-responsiveness to HhAntag is consistent with a lack of stimulation of the Hh pathway in Sufu À/À MEFs after treatment with the Smo agonist, or inhibition after antagonist (cyclopamine) treatment (Svard et al., 2006) . Sufu may also function in concert with other proteins such as MIM/BEG4 or REN (KCTD11) (Callahan et al., 2004; Di Marcotullio et al., 2004) to modulate SHH signaling, in a Smo-independent manner.
However, in one case (case II), Sufu þ /À p53 À/À medulloblastoma allografts responded to drug treatment in a manner similar to Ptch1 þ /À p53 À/À medulloblastoma allografts (Figure 4a ). Therefore, we questioned if this particular case might carry additional mutations to those of Sufu. We used real-time PCR analysis to measure the expression levels of several genes related to the SHH pathway. Allografts in case II expressed Gli1 and Sfrp1 at much higher level compared to allografts from cases I, III and IV or Sufu þ /À p53 À/À primary medulloblastomas. Notably, Ptch1 expression in case II was significantly reduced (Figure 4b ). These data imply that the allografts in case II lost Ptch1 expression, possibly from serial passaging and maintenance of allografts. We also sequenced Ptch1 cDNA from this allograft (case II) and an additional allograft that was insensitive to HhAntag (case I), and found that Ptch1 cDNA from case II contained a large deletion spanning exons 7-14 which results in a truncated protein (data not shown). Taken together with decreased Ptch1 expression, it is likely that Ptch1 became inactivated in this allograft. In contrast, Ptch1 sequenced from the HhAntag allograft not responding to drug treatment did not contain similar mutations. This finding underscores the propensity of murine medulloblastoma to mutate Ptch1, and suggest that Ptch1 loss is dominant to Sufu mutations for regulating tumor growth. Interestingly, medulloblastoma resulting from Xrcc4 deficiency (involved in DNA repair) carried translocation or interstitial deletion of chromosome 13 on which Ptch1 resides, implying that the Ptch1 gene is likely a vulnerable target for mutation associated with genomic instability (Yan et al., 2006) . (Romer et al., 2004; Sasai et al., 2006) . Mice with tumor allografts were treated twice a day (100 mg/kg of body weight) for 4 days and the allografts were harvested 4 h after the last dose of drug, and assessed by measuring the size of the allografts. Cases I and II were obtained from allografts passaged in NOD/SCID mice. Cases III and IV were from primary medulloblastoma samples. primary medulloblastoma (MB) are marked in black. Asterisks indicate absent Ptch1 expression in case II. Ptch1 mutations in allografts were determined as described previously . 
